Gyroscope Therapeutics, a British gene therapy company that has U.S. operations in King of Prussia, has raised $148 million in venture capital funding.
The five-year-old company has now raised about $265 million over three funding rounds since its inception.
Gyroscope’s Series C financing was led by Forbion’s Growth Opportunities Fund. Other investors are Sofinnova Investments, funds and accounts advised by T. Rowe Price Associates, Tetragon Financial Group Limited, an undisclosed healthcare focused fund, Fosun Pharma, Cambridge Innovation Capital and founding investor Syncona.
The five-year-old company plans to use the proceeds from the stock sale to advance the development of its lead gene therapy candidate, GT005, a potential treatment for geographic atrophy secondary to age-related macular degeneration.
Read the full article at: www.bizjournals.com
Latest posts by Chris Frew (see all)
- [Podcast] Grow Your Career in Biotech with Chris Frew - June 28, 2021
- In a Year of Crisis, Maryland Biotech Responds with Leadership - June 8, 2021
- Baltimore’s Port Covington Project Looks To Life Sciences - June 8, 2021
- Maryland Chamber Foundation’s Teacher Externship Program Grows by 766% in 2021 - June 2, 2021
- These life sciences jobs could triple. Inside the big effort to train workers. - May 20, 2021